# Imaging With a New Agent That Finds a Cancer Protein Called HER2

> **NCT03109977** · PHASE1 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 6 (actual)

## Conditions studied

- HER2-positive Carcinoma
- HER2-positive Primary Malignancy

## Interventions

- **DRUG:** Zr-DFO-pertuzumab PET/CT

## Key facts

- **NCT ID:** NCT03109977
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-31
- **Primary completion:** 2018-04-12
- **Final completion:** 2018-04-12
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2018-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03109977

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03109977, "Imaging With a New Agent That Finds a Cancer Protein Called HER2". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03109977. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*